BR0206819A - Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca - Google Patents

Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca

Info

Publication number
BR0206819A
BR0206819A BR0206819-2A BR0206819A BR0206819A BR 0206819 A BR0206819 A BR 0206819A BR 0206819 A BR0206819 A BR 0206819A BR 0206819 A BR0206819 A BR 0206819A
Authority
BR
Brazil
Prior art keywords
heart disease
prevention
treatment
inhibitors
inhibitor
Prior art date
Application number
BR0206819-2A
Other languages
English (en)
Inventor
Charles Dinarello
Benjamin Pomerantz
Leonid Reznikov
Alden Harken
Yolande Chvatchko
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BR0206819A publication Critical patent/BR0206819A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"USO DE INIBIDORES DE IL-18 PARA O TRATAMENTO E/OU PARA A PREVENçãO DE DOENçA CARDìACA". A presente invenção refere-se ao uso de um inibidor da IL-18 na preparação de um medicamento para o tratamento e/ou para a prevenção de uma doença cardíaca, em particular de uma doença cardíaca isquêmica. São também consideradas combinações de um inibidor da IL-18 e/ou de um antagonista do TNF para o tratamento elou para a prevenção de uma doença cardíaca.
BR0206819-2A 2001-01-29 2002-01-28 Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca BR0206819A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29
PCT/EP2002/000844 WO2002060479A1 (en) 2001-01-29 2002-01-28 Use of il-18 inhibitors for the treatment and/or prevention of heart disease

Publications (1)

Publication Number Publication Date
BR0206819A true BR0206819A (pt) 2004-02-03

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206819-2A BR0206819A (pt) 2001-01-29 2002-01-28 Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca

Country Status (32)

Country Link
US (1) US20040234523A1 (pt)
EP (1) EP1355668B1 (pt)
JP (2) JP4860897B2 (pt)
KR (1) KR100857376B1 (pt)
CN (1) CN1326562C (pt)
AR (1) AR032422A1 (pt)
AT (1) ATE380558T1 (pt)
BG (1) BG66483B1 (pt)
BR (1) BR0206819A (pt)
CA (1) CA2435466C (pt)
CY (1) CY1107203T1 (pt)
CZ (1) CZ305653B6 (pt)
DE (1) DE60224004T2 (pt)
DK (1) DK1355668T3 (pt)
EA (2) EA010180B1 (pt)
EE (1) EE05534B1 (pt)
ES (1) ES2295332T3 (pt)
HK (1) HK1062810A1 (pt)
HR (1) HRP20030609A2 (pt)
HU (1) HU229164B1 (pt)
IL (2) IL157024A0 (pt)
ME (1) ME00549B (pt)
MX (1) MXPA03006776A (pt)
NO (1) NO331083B1 (pt)
PL (1) PL213568B1 (pt)
PT (1) PT1355668E (pt)
RS (1) RS51125B (pt)
SI (1) SI1355668T1 (pt)
SK (1) SK287620B6 (pt)
UA (1) UA80676C2 (pt)
WO (1) WO2002060479A1 (pt)
ZA (1) ZA200305439B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520392A (en) 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
EP2357002A1 (en) 2000-10-11 2011-08-17 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
ATE557038T1 (de) 2005-06-03 2012-05-15 Ares Trading Sa Herstellung von rekombinantem il-18 bindendem protein
EP1891088B1 (en) 2005-06-10 2011-10-19 Ares Trading S.A. Process for the purification of il-18 binding protein
JP5968590B2 (ja) 2007-11-05 2016-08-10 ケーシーアイ ライセンシング インコーポレイテッド 創面切除のための組織の同定
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
EP3041864B1 (en) * 2013-09-05 2021-07-21 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
AU2016227644B2 (en) * 2015-03-05 2022-06-16 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) and antibodies in inflammatory diseases
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
IL125190A (en) * 1996-09-12 2003-01-12 Idun Pharmaceuticals Inc Tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes and pharmaceutical compositions containing the same
WO1998024804A2 (en) * 1996-12-06 1998-06-11 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
CN1269722A (zh) * 1997-03-18 2000-10-11 Basf公司 调节对皮质类固醇反应的方法及组合物
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
WO2000000490A2 (en) * 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
WO2000055114A1 (en) * 1999-03-16 2000-09-21 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
CN1176941C (zh) * 1999-04-09 2004-11-24 西托维亚公司 Caspase抑制剂及其应用
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
PT1278540E (pt) * 2000-05-05 2008-07-03 Inst Nat Sante Rech Med Utilização de inibidores da il-18 para o tratamento e/ou prevenção de aterosclerose
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
CZ20032335A3 (en) 2004-07-14
SI1355668T1 (sl) 2008-06-30
YU57803A (sh) 2006-05-25
CZ305653B6 (cs) 2016-01-27
ATE380558T1 (de) 2007-12-15
CN1326562C (zh) 2007-07-18
WO2002060479A1 (en) 2002-08-08
JP2004522748A (ja) 2004-07-29
US20040234523A1 (en) 2004-11-25
DK1355668T3 (da) 2008-05-05
UA80676C2 (en) 2007-10-25
JP4860897B2 (ja) 2012-01-25
IL157024A0 (en) 2004-02-08
EA200501549A1 (ru) 2006-04-28
IL157024A (en) 2014-02-27
BG108128A (bg) 2004-11-30
EA006767B1 (ru) 2006-04-28
RS51125B (sr) 2010-10-31
KR100857376B1 (ko) 2008-09-05
BG66483B1 (bg) 2015-03-31
MXPA03006776A (es) 2003-10-24
KR20030070143A (ko) 2003-08-27
SK287620B6 (sk) 2011-04-05
EE200300328A (et) 2003-10-15
CN1499982A (zh) 2004-05-26
HUP0303306A3 (en) 2005-12-28
NO20033228D0 (no) 2003-07-16
CA2435466A1 (en) 2002-08-08
HK1062810A1 (en) 2004-11-26
NO331083B1 (no) 2011-10-03
HRP20030609A2 (en) 2005-06-30
SK10892003A3 (sk) 2004-02-03
EP1355668A1 (en) 2003-10-29
PL213568B1 (pl) 2013-03-29
DE60224004D1 (de) 2008-01-24
EA010180B1 (ru) 2008-06-30
PT1355668E (pt) 2008-01-04
EP1355668B1 (en) 2007-12-12
CA2435466C (en) 2012-04-03
PL366802A1 (en) 2005-02-07
HUP0303306A2 (hu) 2004-01-28
HU229164B1 (en) 2013-09-30
CY1107203T1 (el) 2012-11-21
ME00549B (me) 2011-10-10
AR032422A1 (es) 2003-11-05
ES2295332T3 (es) 2008-04-16
EA200300844A1 (ru) 2003-12-25
DE60224004T2 (de) 2009-07-23
NO20033228L (no) 2003-09-26
EE05534B1 (et) 2012-04-16
JP2009102354A (ja) 2009-05-14
ZA200305439B (en) 2004-07-15

Similar Documents

Publication Publication Date Title
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2004041269A3 (en) New use for pharmaceutical composition
EE05423B1 (et) IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
BR0014003A (pt) Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
BR9810520A (pt) Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial
SE0101932D0 (sv) Pharmaceutical combinations
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
BR0213181A (pt) Combinações de inibidor de cox-2
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
BR0211827A (pt) Uso de inibidores de il-18 em distúrbios de hipersensibilidade
BR0113886A (pt) Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
WO2005035746A3 (en) Medical use of tbk-1 or of inhibitors thereof
ECSP055804A (es) Composición farmacéutica
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SERONO S.A. (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]